2022 World Conference on Lung Cancer (ePosters)-EP16.01-014. Characterisation of Circulating Immune Cells in a Cohort of Non-small Cell Lung Cancer Patients Treated with Immunotherapy

EP16.01-014. Characterisation of Circulating Immune Cells in a Cohort of Non-small Cell Lung Cancer Patients Treated with Immunotherapy

Back to course

Pdf Summary

This study aimed to analyze the circulating immune cell populations in a cohort of patients with non-small cell lung cancer (NSCLC) who were treated with immune-checkpoint inhibitors (ICI). The researchers collected demographic, clinical, and tumor data from 55 patients and analyzed 43 cell subpopulations of CD4 and CD8 T and NK cells in peripheral blood samples. These cell subpopulations included markers for exhaustion, differentiation, memory, activation, and inhibition. The objective was to identify prognostic biomarkers that could predict the efficacy of immunotherapy in NSCLC.<br /><br />The results showed that 56.4% of the patients progressed after a minimum of one year of follow-up, with a median overall survival of 19 months. The descriptive analysis of the cell populations revealed that Granzyme B CD4 T lymphocytes with regulatory properties had a median of 17.4%. Memory CD4 and CD8 T lymphocytes had a median of 4.9% and 3.5%, respectively. The CD8 T /CD4 T regulatory cell ratio had a median of 1. The majority of the patients had activated cytotoxic NK cells, and around half of them had highly differentiated adaptive-like NK cells. However, a significant proportion of patients did not express activating receptors on their NK cells, suggesting the presence of dysfunctional NK cell subsets.<br /><br />The researchers concluded that circulating immune cell subpopulations have the potential to be important prognostic biomarkers for ICI in NSCLC. They provided a detailed descriptive analysis of the main circulating T and NK cell subsets involved in cancer immunity in this cohort of patients. The study also suggested the presence of dysfunctional T and NK cell responses that may be related to the efficacy of immunotherapy. Further research is needed to determine the significance of these findings in predicting survival and treatment outcomes in NSCLC patients.

Asset Subtitle

Marta Gascón- Ruiz

Meta Tag

Speaker Marta Gascón- Ruiz

Topic Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

Keywords

non-small cell lung cancer

immune-checkpoint inhibitors

CD4 T cells

CD8 T cells

NK cells

prognostic biomarkers

immunotherapy

circulating immune cell populations

dysfunctional NK cell subsets

treatment outcomes